CLA-2-30:RR:NC:2:238 D80776
Ms. Carol D. Gillis
SmithKline Beecham Pharmaceuticals
One Franklin Plaza
200 North !6th Street
Philadelphia, PA 19102
RE: The tariff classification of Engerix-B [Hepatitis B Vaccine
(Recombinant)] from Belgium
Dear Ms. Gillis:
In your letter dated July 23, 1998, you requested a tariff
classification ruling.
The subject product, Engerix-B , is a noninfectious
recombinant DNA hepatitis B vaccine. It contains purified
surface antigen of the virus obtained by culturing genetically
engineered Saccharomyces cerevisiae cells, which carry the
surface antigen gene of the hepatitis B virus. Engerix-B is
indicated for immunization against infection caused by all known
subtypes of hepatitis B virus.
The applicable subheading for Engerix-B , imported in bulk
form or in measured doses, will be 3002.20.0000, Harmonized
Tariff Schedule of the United States (HTS), which provides for:
"Vaccines for human medicine." The rate of duty will be free.
This merchandise may be subject to the requirements of the
Federal Food, Drug, and Cosmetic Act, which is administered by
the U.S. Food and Drug Administration. You may contact them at
5600 Fishers Lane, Rockville, Maryland 20857, telephone number
(301) 443-6553.
This ruling is being issued under the provisions of Part 177
of the Customs Regulations (19 C.F.R. 177).
A copy of the ruling or the control number indicated above
should be provided with the entry documents filed at the time
this merchandise is imported. If you have any questions
regarding the ruling, contact National Import Specialist Harvey
Kuperstein at 212-466-5770.
Sincerely,
Robert B. Swierupski
Director,
National Commodity
Specialist Division